The percent of placebo-corrected changes from baseline for LDL-C ( estimated by Friedewald calculation [ Fc-LDL-C ] ) and HDL-C after 24weeks of anacetrapib 100mg/day were compared among patients by age , gender , race , diabetes status , type of concomitant statin with or without other lipid therapies , and baseline HDL-C , Fc-LDL-C , and triglyceride ( TG ) levels .